Pulmonary Hypertension Clinical Trials 2024

What are the top hospitals conducting pulmonary hypertension research?

When it comes to the complex and often misunderstood condition of pulmonary hypertension, several hospitals are leading the way in cutting-edge clinical trials. In Boston, Massachusetts General Hospital stands out with four active trials dedicated to this challenging disease, along with a remarkable track record of 28 completed studies. Since initiating their first trial in 2002, they have been at the forefront of research and innovation for pulmonary hypertension treatment. Meanwhile, on the East Coast in Baltimore, the University of Maryland Medical Center has also made significant contributions with three ongoing trials and seven previously conducted ones since their debut study in 2012.

Traveling down south to Gainesville, Florida, we find that the University of Florida is making strides as well; currently conducting three active clinical trials focused on pulmonary hypertension while having successfully completed nine previous investigations since their inaugural trial began in 2006. Not far from there is Tufts Medical Center in Boston where researchers are actively engaged in three pivotal pulmonary hypertension clinical trials alongside completing twenty-seven other important research projects on this subject after starting off back almost two decades ago duringthe year2005.

Lastly but certainly not leastly,the University of Colorado Hospital locatedin Aurora continuescontributingto our understandingofpulmonaryhypertensionwiththreeactiveclinicaltrials.The noteworthy aspect hereis thatalthoughtherehaveonlybeenthreecompletedtrialssincetheirfirstinvestigationwasinitiatedin2017,thisinstitutionhas managedtomakea significantsplashinthefieldanddemonstratetheirexpertiseanddedicationtowardsthisseverelyunderdiagnosedcondition

As these top hospitals continue to push boundaries and explore new avenues for treating pulmonary hypertension patients worldwide can take comfort knowing that dedicated experts are tirelessly working towards improved outcomes and breakthroughs for this debilitating condition

Which are the best cities for pulmonary hypertension clinical trials?

When it comes to pulmonary hypertension clinical trials, several cities excel in conducting cutting-edge research. Los Angeles, California; Boston, Massachusetts; Indianapolis, Indiana; Houston, Texas; and Philadelphia, Pennsylvania are among the top cities with active trials. These studies focus on a range of experimental treatments such as Ralinepag, Sotatercept 0.3 mg/kg (escalating to 0.7 mg/kg), Macitentan, MK-5475, Selexipag, and Long Term Follow Up protocols. With their extensive involvement in ongoing research efforts for pulmonary hypertension treatment options, these cities offer individuals affected by this condition access to promising clinical trials that may lead to improved care outcomes.

Which are the top treatments for pulmonary hypertension being explored in clinical trials?

Pulmonary hypertension research is advancing, with a focus on exploring effective treatments in clinical trials. Leading the way is Ralinepag, currently being tested in two active trials for pulmonary hypertension. Since its introduction in 2018, it has been involved in three all-time clinical trials dedicated to this condition. Another promising contender is MK-5475, which recently made its debut and already has one ongoing trial for pulmonary hypertension among its three all-time trials. These innovative treatments hold promise for improving the lives of patients battling this challenging disease.

What are the most recent clinical trials for pulmonary hypertension?

Recent clinical trials offer hope for individuals with pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. Among these trials is Hyperpolarized 129Xe, which has entered Phase 2 and shows promise as a potential treatment option. Additionally, AZD3427 Dose A and Treprostinil Palmitil have also progressed to Phase 2, providing further opportunities for advancing therapeutic interventions. These studies aim to improve our understanding and management of pulmonary hypertension, ultimately enhancing patient outcomes and quality of life.

What pulmonary hypertension clinical trials were recently completed?

Several notable clinical trials focusing on pulmonary hypertension have recently concluded, shedding light on potential advancements in the treatment of this condition. Actelion's trial for Selexipag reached completion in February 2021, offering insights into its effectiveness. Additionally, the University of Washington successfully completed a trial exploring the use of Famotidine 20 MG in May 2019. In January 2019, Northwell Health completed their investigation into Alteplase as a potential therapy for pulmonary hypertension. These recent trials contribute to our understanding and pave the way for further breakthroughs in combatting this challenging disease.